Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.53 |
| ▸ | CHKA | P35790 | 13/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15211999 | 0.98 | CHKA (0.56) | CHKABCHEACHE | |
| Water SCHEMBL15212777 | 0.96 | CHKA (0.54) | CHKABCHEACHE | |
| Iodide SCHEMBL15211901 | 0.91 | CHKA (0.56) | CHKABCHEACHE | |
| Iodide SCHEMBL15212212 | 0.89 | CHKA (0.58) | CHKABCHEACHE | |
| SCHEMBL15212015 | 0.87 | CHKA (0.59) | CHKABCHEACHE | |
| Water SCHEMBL15212784 | 0.85 | CHKA (0.58) | CHKABCHEACHE | |
| Iodide SCHEMBL15212150 | 0.83 | CHKA (0.59) | CHKABCHEACHE | |
| SCHEMBL18102253 | 0.81 | KDM4A (0.50) | CHKABCHEACHEKDM4EHTT | |
| SCHEMBL9328178 | 0.81 | CHKA (0.61) | CHKABCHEACHE | |
| Iodide SCHEMBL15212342 | 0.80 | CHKA (0.59) | CHKABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890050-B2 | Molecular sieve material, its synthesis and use | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2817262-B1 | MOLECULAR SIEVE MATERIAL, ITS SYNTHESIS AND USE | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20160368778-A1 | Molecular Sieve Material, Its Synthesis and Use | EXXONMOBIL CHEMICAL PATENTS INC. | 2016-12-22 | — | — | US | disclosed |
| US-9452423-B2 | Molecular sieve material, its synthesis and use | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150025291-A1 | Molecular Sieve Material, Its Synthesis and Use | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-01-22 | — | — | US | disclosed |
| EP-2817262-A1 | MOLECULAR SIEVE MATERIAL, ITS SYNTHESIS AND USE | ExxonMobil Chemical Patents Inc. (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013126140-A1 | MOLECULAR SIEVE MATERIAL, ITS SYNTHESIS AND USE | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025291-A1 | Molecular Sieve Material, Its Synthesis and Use | RPS17, MMP17, MRPS27 | ACHE 4404/4885CHKA 4726/4885BCHE 4848/4885 |
| US-20160368778-A1 | Molecular Sieve Material, Its Synthesis and Use | MMP17, RPS17, CDK17 | ACHE 4357/4885CHKA 4718/4885BCHE 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.